Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Hiroaki Shimmura
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Related publications
Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma: A Phase 1b Study
American Journal of Hematology
Hematology
Carfilzomib Monotherapy in Japanese Patients With Relapsed or Refractory Multiple Myeloma: A Phase 1/2 Study
Cancer Science
Cancer Research
Medicine
Oncology
Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma
European Journal of Medical Research
Medicine
Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Isatuximab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design
Future Oncology
Medicine
Cancer Research
Oncology
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
Cancers
Cancer Research
Oncology
Emerging Role of Carfilzomib in Treatment of Relapsed and Refractory Lymphoid Neoplasms and Multiple Myeloma
Core Evidence
Medicine
Reviews
References
Pharmacology
A Phase I/Ii Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
Clinical Cancer Research
Cancer Research
Oncology
Optimizing the Use of Lenalidomide in Relapsed or Refractory Multiple Myeloma: Consensus Statement
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology